Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06493019 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
A Phase 2 study of Anal Cancer, sponsored by Dustin Deming.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT06493019: Recruiting Phase 2 study of Anal Cancer, sponsored by Dustin Deming.
NCT06493019 is a Phase 2 study of Anal Cancer that is actively recruiting participants, run by Dustin Deming. The registered enrollment target is 23 participants, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06493019, a Phase 2 study of Anal Cancer, is actively recruiting participants, sponsored by Dustin Deming.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenance phase (Cycle 7-14, 6 week cycles).
Primary Outcome
Meets both of the following criteria: 1. There is no documented residual cancer on anoscopy. If residual cancer is suspected, a biopsy must be obtained. 2. No documented residual cancer or new metastatic disease on PET/CT, or if a PET/CT cannot be obtained, CT or MR imaging with contrast can be used. Physiologic PET avidity in the anal canal without evidence of cancer on anoscopy is still consistent with a clinical complete response.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiation
Study Locations (4)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Maryland
- University of Maryland - Baltimore
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2029-04-14 |
| Phase | Phase 2 |
What NCT06493019 shows while recruiting
NCT06493019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 579-participant average among 19 other Anal Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT06493019 reports a single indexed study location in Indiana, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06493019 about?
NCT06493019 is a clinical study titled "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer". A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (Cycle 1-6, weekly cycles) which is followed by the maintenanc...
What is the current status of trial NCT06493019?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2024-09-30. Estimated completion is 2029-04-14.
What conditions does trial NCT06493019 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT06493019?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT06493019?
This trial is sponsored by Dustin Deming, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06493019 being conducted?
This trial has 4 study locations across Indiana, Maryland, New Jersey, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06493019's enrollment target sits among peer trials
23 15th of 19 higher than 5 of 19 other Anal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
ACTIVE NOT RECRUITING · Phase 2
-
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
COMPLETED · Phase 2
-
Pembrolizumab in Metastatic Anal Cancer
COMPLETED · Phase 2
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI